Valuation: H&R GmbH & Co KgaA

Market Cap 208M 238M 192M 179M 339M 22.7B 344M 2.3B 894M 11.16B 895M 876M 38.45B P/E 2026 *
35.6x
P/E 2027 * 26.3x
Enterprise Value 365M 417M 335M 312M 592M 39.71B 601M 4.02B 1.56B 19.52B 1.57B 1.53B 67.25B EV / Sales 2026 *
0.28x
EV / Sales 2027 * 0.28x
Free-Float
21.97%
Yield 2026 *
0.89%
Yield 2027 * 0.89%
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25/08/25 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
15/08/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
16/05/25 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
14/05/25 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
16/04/25 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
09/04/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
26/03/25 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
26/03/25 H&R GmbH & Co. KGaA Announces Postponement of the Publication of the Consolidated Financial Statements and the Annual Report 2024 CI
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2016
Investor Relations Contact - 01/01/2006
Director TitleAgeSince
Chairman 62 17/04/2012
Director/Board Member 71 01/05/2011
Director/Board Member 69 01/05/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 239M
+0.16%+4.30%+12.73%+32.69% 131B
0.00%+27.10%+594.89%+171.72% 48.98B
-1.33%-2.54%-7.59%-41.85% 41.35B
+0.85%-6.02%+27.61%-21.24% 31.62B
0.00%-2.98%+25.40%+62.89% 21.99B
-9.99%-2.85%+70.29%+258.13% 21.79B
-2.23%-1.52%+440.96%+652.36% 20.18B
-1.59%-7.88%+82.36%+3.30% 18.04B
+0.56%-2.25%+25.18%+24.21% 18.34B
Average -1.36%+1.40%+141.31%+126.91% 39.23B
Weighted average by Cap. -0.82%+4.48%+125.47%+87.69%

Financials

2026 *2027 *
Net sales 1.29B 1.48B 1.19B 1.11B 2.1B 141B 2.13B 14.27B 5.55B 69.25B 5.55B 5.43B 239B 1.33B 1.52B 1.22B 1.14B 2.16B 145B 2.19B 14.68B 5.71B 71.22B 5.71B 5.59B 245B
Net income 5.85M 6.69M 5.37M 5.01M 9.5M 637M 9.65M 64.53M 25.08M 313M 25.11M 24.57M 1.08B 8M 9.15M 7.35M 6.85M 12.99M 871M 13.19M 88.21M 34.29M 428M 34.33M 33.59M 1.47B
Net Debt 156M 179M 143M 134M 254M 17B 257M 1.72B 670M 8.36B 670M 656M 28.8B 158M 181M 145M 135M 256M 17.19B 260M 1.74B 677M 8.45B 678M 663M 29.12B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-